Latest Manufacturing News

Page 17 of 335
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Talga has signed a binding term sheet with Japan’s Dainen Materials to reserve up to 2,000 tonnes a year of Talnode-C anode material for five years from late 2027. The agreement advances Talga’s commercialisation, but final purchase volumes and a definitive supply contract remain outstanding.
Victor Sage
Victor Sage
28 Oct 2026
RLF AgTech improved margins and cut its quarterly loss sharply, even as revenue fell 18%. The more pressing issue is cash: operating outflow more than doubled to $3.6 million, leaving the fertiliser group with an estimated 1.8 quarters of funding.
Ada Torres
Ada Torres
28 Oct 2026
West African Resources delivered record quarterly gold production of 127,950 ounces and generated A$458.2 million in operating cash flow, lifting cash to A$1.195 billion. The strong quarter keeps 2026 production guidance within reach, while Kiaka’s explosives constraint and a pending ownership transaction remain key execution issues.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Barramundi’s portfolio returned 3.0% on a gross basis in the September quarter, ahead of the ASX 200’s 1.3% gain. CSL, Ansell, MAAS Group and PWR Holdings led the recovery, although the NZX-listed investment company still traded at a 17.2% discount to NAV.
Victor Sage
Victor Sage
28 Oct 2026
Kingfish delivered a 10.2% gross return in the six months to September, but its shares ended the quarter at a 15.5% discount to NAV. The investment company also added Skellerup to its portfolio as Delegat, Vista and Fisher & Paykel Healthcare led quarterly gains.
Victor Sage
Victor Sage
28 Oct 2026
Jatcorp’s Q1 FY27 revenue fell 52.4% to A$4.66 million as a sharper seasonal downturn in China hit brand sales and OEM orders. Cash fell to A$3.727 million after A$2.145 million of operating outflows, leaving the company’s reported funding estimate at 1.7 quarters.
Victor Sage
Victor Sage
27 Oct 2026
Clean TeQ Water delivered a stronger FY26, with revenue up 71% to A$19.7 million, positive operating cash flow and a narrowed loss. The bigger shift is commercial: major water and critical-minerals contracts are moving into execution while the Rasp Mine agreement creates the company’s first recurring revenue stream.
Victor Sage
Victor Sage
27 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Fleetwood enters FY27 with a stronger Community Solutions business, a $61.5 million net cash position and a plan to restore Building Solutions to profitability in the second half. The key tests are completing the Red Dog Village acquisition and proving its manufacturing reset can overcome a $8.7 million underlying loss.
Victor Sage
Victor Sage
27 Oct 2026
Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive